AM Rx vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
AM Rx
Best for patients with insurance seeking brand-name GLP-1 access (review regulatory warnings carefully)Starting at $25/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | AM Rx | Wisp |
|---|---|---|
| Overall Score | 5.9/10 | ✓7.0/10 |
| Starting Price | ✓$25/mo | $225/mo |
| Editorial Rating | 3 ★ /5 | ✓3.5 ★ /5 |
| Features | 6 features | 6 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | 2 warnings | ✓None |
Pros & Cons
AM Rx
Pros
- ✓Insurance coordination for brand-name GLP-1s — as low as $25/mo
- ✓All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- ✓HSA and FSA accepted
- ✓Video visits available (not just async) with providers averaging 10+ years experience
- ✓Compounded semaglutide from $151/mo quarterly
Cons
- ✗Active FTC/DOJ lawsuit for deceptive billing and subscription practices (ROSCA violations)
- ✗Two FDA warning letters (Sept 2025, Feb 2026) for misbranding compounded GLP-1 products
- ✗Novo Nordisk false advertising lawsuit (Aug 2025)
- ✗Parent entity Zealthy has BBB D- rating with 2,370+ complaints
- ✗Trustpilot 2.0/5 — 85% one-star reviews citing billing disputes and unreachable support
- ✗No visible LegitScript certification or PCAB accreditation
- ✗No named pharmacy partners — compounding source not disclosed
- ✗No FDA compounding disclaimer on the website
- ✗State availability not publicly disclosed
- ✗Founder Kyle Robertson previously ran Cerebral, which settled FTC charges for similar practices
- ✗Same corporate entity (FitRX LLC) as Zealthy and FitRx — shares regulatory history
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
Wisp edges out AM Rx with a higher overall score of 7.0/10 and is particularly strong for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested. AM Rx remains a solid alternative, especially if you're looking for patients with insurance seeking brand-name GLP-1 access (review regulatory warnings carefully).
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.